Home » Stocks » VIRI

Virios Therapeutics, Inc. (VIRI)

Stock Price: $8.16 USD -0.18 (-2.16%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $8.00 -0.16 (-1.96%) Jan 15, 7:27 PM
Market Cap 67.59M
Revenue (ttm) n/a
Net Income (ttm) -2.57M
Shares Out 7.83M
EPS (ttm) -0.33
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $8.16
Previous Close $8.34
Change ($) -0.18
Change (%) -2.16%
Day's Open 8.20
Day's Range 7.90 - 8.45
Day's Volume 257,031
52-Week Range 7.33 - 16.71

News

Hide News
Business Wire - 1 week ago

ATLANTA--(BUSINESS WIRE)--Virios Therapeutics, Inc. (VIRI) will present at the H.C. Wainwright Virtual BioConnect Conference, taking place January 11-14, 2021.

Business Wire - 3 weeks ago

ATLANTA--(BUSINESS WIRE)--Virios Therapeutics, Inc. (Nasdaq: VIRI), a biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered a...

Business Wire - 1 month ago

ATLANTA--(BUSINESS WIRE)--Virios Therapeutics, Inc. (the “Company”), a biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered ...

About VIRI

Virios Therapeutics, LLC, a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. Its lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, LLC in July 2020. Virios Therapeutics, LLC was founded in 2012 and is headquartered in Alpharetta, Georgia.

Industry
Biotechnology
IPO Date
Dec 17, 2020
CEO
Greg Duncan
Employees
4
Stock Exchange
NASDAQ
Ticker Symbol
VIRI
Full Company Profile

Financial Performance

Financial Statements